This news is of great interest to our firm. Like the government, plaintiffs in lawsuits involving Risperdal and gynecomastia have alleged that the drug was improperly marketed to children.
New York, NY (PRWEB) November 04, 2013
As Risperdal lawsuits (http://www.therisperdallawsuit.com) involving allegations that use of the antipsychotic drug caused gynecomastia, or male breast growth, continue to mount in courts throughout the country, Bernstein Liebhard LLP notes that Johnson & Johnson has agreed to pay $2.2 billion to settle a government probe into the marketing of some of its drugs, including Risperdal. According to a press release issued today by the U.S. Department of Justice, the settlement includes $4.85 million in criminal fines, and $1.72 billion in civil penalties. Among other things, the agreement resolves charges that Johnson & Johnson misbranded Risperdal and promoted off-label use of the drug for children, elderly nursing home patients, and those with mental disabilities.*
“This news is of great interest to our firm. Like the government, plaintiffs in lawsuits involving Risperdal and gynecomastia have alleged that the drug was improperly marketed to children,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.
Risperdal is approved to treat schizophrenia in adults and adolescents, bipolar disorder in adults and children ages 10-to-17, and to reduce irritability in children (5-to-16 years of age) with autistic disorder.*** Research also indicates that off- label use of Risperdal to treat ADHD is also on the rise.****
Risperdal may cause the body to produce excessive amounts of a hormone called prolactin, according to a 2006 study published in the Journal of Clinical Psychopharmacology. Excessive levels of prolactin were associated with gynecomastia in boys and the development of lactation in girls, according to the study authors. *****
According to a previous report from Bloomberg.com, scores of Risperdal lawsuits have been filed against Johnson & Johnson over allegations that use of the drug can lead to male breast growth. In October 2012, Johnson & Johnson agreed to settle five claims involving Risperdal and gynecomastia that had been filed in Pennsylvania state court. Among other things, the lawsuits alleged that Johnson & Johnson knew use of the drug could lead to male breast development, and that its sales reps were trained to downplay this potential Risperdal side effect. The Plaintiffs also alleged that Risperdal was illegally marketed for use in children.****** (A.B., a minor v. Janssen Pharmaceuticals, 00649, Philadelphia Court of Common Pleas)
According to today’s Bloomberg.com report, the U.S. Justice Department has been probing Risperdal sales practices since 2004, including allegations that the company illegally marketed the drug for use in children and elderly dementia patients.
Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, pain and suffering, emotional distress, and other injury-related damages. Learn More about filing a Risperdal lawsuit at Bernstein Liebhard LLP’s website. For a free case review, please contact the Firm by calling 800-511-5092.
*Justice.gov/opa/pr/2013/November/13-ag-1170.html?source=email_rt_mc_body&app=n, U.S. Department of Justice, November 4, 2013
**bloomberg.com/news/2013-11-04/j-j-settlement-over-risperdal-said-to-be-announced-today.html. Bloomberg.com, November 4, 2013
***accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
****health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
*****journals.lww.com/psychopharmacology/Abstract/2006/04000/Risperidone_induced_Symptomatic.10.aspx, Journal of Clinical Psychopharmacology, April 2006
******Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com